Colon Carcinoma Cells Induce CXCL11-dependent Migration of CXCR3-expressing Cytotoxic T Lymphocytes in Organotypic Culture

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2006 Jun 20

PMID 16783574

Citations 14

Authors

Klara Berencsi

Neal J Meropol

John P Hoffman

Elin Sigurdson

Lydia Giles

Pyapalli Rani

Rajasekharan Somasundaram

Tianqian Zhang

Jiri Kalabis

Laura Caputo

Emma Furth

Rolf Swoboda

Francesco Marincola

Dorothee Herlyn

Affiliations

Soon will be listed here.

Abstract

Adoptive immunotherapy of cancer patients with cytolytic T lymphocytes (CTL) has been hampered by the inability of the CTL to home into tumors in vivo. Chemokines can attract T lymphocytes to the tumor site, as demonstrated in animal models, but the role of chemokines in T-lymphocyte trafficking toward human tumor cells is relatively unexplored. In the present study, the role of chemokines and their receptors in the migration of a colon carcinoma (CC) patient's CTL toward autologous tumor cells has been studied in a novel three-dimensional organotypic CC culture. CTL migration was mediated by chemokine receptor CXCR3 expressed by the CTL and CXCL11 chemokine secreted by the tumor cells. Excess CXCL11 or antibodies to CXCL11 or CXCR3 inhibited migration of CTL to tumor cells. T cell and tumor cell analyses for CXCR3 and CXCL11 expression, respectively, in ten additional CC samples, may suggest their involvement in other CC patients. Our studies, together with previous studies indicating angiostatic activity of CXCL11, suggest that CXCL11 may be useful as an immunotherapeutic agent for cancer patients when transduced into tumor cells or fused to tumor antigen-specific Ab.

Citing Articles

CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.

Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X Mol Ther. 2022; 31(1):134-153.

PMID: 36056553 PMC: 9840126. DOI: 10.1016/j.ymthe.2022.08.021.

CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.

Gao H, Cheng C, Tang J, Li Y, Chen H, Meng Z Aging (Albany NY). 2020; 12(1):502-517.

PMID: 31913856 PMC: 6977695. DOI: 10.18632/aging.102638.

Ecker B, Kaur A, Douglass S, Webster M, Almeida F, Marino G Cancer Discov. 2018; 9(1):82-95.

PMID: 30279172 PMC: 6328344. DOI: 10.1158/2159-8290.CD-18-0168.

Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.

Moon E, Wang L, Bekdache K, Lynn R, Lo A, Thorne S Oncoimmunology. 2018; 7(3):e1395997.

PMID: 29399394 PMC: 5790399. DOI: 10.1080/2162402X.2017.1395997.

Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer.

Kistner L, Doll D, Holtorf A, Nitsche U, Janssen K Oncotarget. 2017; 8(52):89998-90012.

PMID: 29163806 PMC: 5685727. DOI: 10.18632/oncotarget.21286.

References

Hauser A, Debes G, Arce S, Cassese G, Hamann A, Radbruch A . Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol. 2002; 169(3):1277-82. DOI: 10.4049/jimmunol.169.3.1277. View

Guidoboni M, Gafa R, Viel A, Doglioni C, Russo A, Santini A . Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol. 2001; 159(1):297-304. PMC: 1850401. DOI: 10.1016/S0002-9440(10)61695-1. View

Tensen C, Flier J, Sampat-Sardjoepersad S, van der Schors R, Leurs R, Scheper R . Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol. 1999; 112(5):716-22. DOI: 10.1046/j.1523-1747.1999.00581.x. View

Aiba S, Nakagawa S, Hara M, Tomioka Y, Deguchi M, Tagami H . Cultured murine dermal cells can function like thymic nurse cells. J Invest Dermatol. 1994; 103(2):162-7. DOI: 10.1111/1523-1747.ep12392632. View

Hellmuth M, Paulukat J, Ninic R, Pfeilschifter J, Muhl H . Nitric oxide differentially regulates pro- and anti-angiogenic markers in DLD-1 colon carcinoma cells. FEBS Lett. 2004; 563(1-3):98-102. DOI: 10.1016/S0014-5793(04)00275-3. View

Sauty A, Colvin R, Wagner L, Rochat S, Spertini F, Luster A . CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). J Immunol. 2001; 167(12):7084-93. DOI: 10.4049/jimmunol.167.12.7084. View

Murakami S, Okada H . Lymphocyte-fibroblast interactions. Crit Rev Oral Biol Med. 1997; 8(1):40-50. DOI: 10.1177/10454411970080010201. View

Stark H, Fusenig N . Keratinocyte growth regulation in defined organotypic cultures through IL-1-induced keratinocyte growth factor expression in resting fibroblasts. J Invest Dermatol. 2000; 114(6):1075-84. DOI: 10.1046/j.1523-1747.2000.00987.x. View

Robertson M . Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002; 71(2):173-83. View

10.

Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S . Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 2002; 62(18):5267-72. View

11.

Cole K, Strick C, Paradis T, Ogborne K, Loetscher M, Gladue R . Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med. 1998; 187(12):2009-21. PMC: 2212354. DOI: 10.1084/jem.187.12.2009. View

12.

Gohara R, Nakao M, Ogata Y, Isomoto H, Oizumi K, Itoh K . Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer. Jpn J Cancer Res. 1997; 88(2):198-204. PMC: 5921357. DOI: 10.1111/j.1349-7006.1997.tb00366.x. View

13.

Maaser K, Wolf K, Klein C, Niggemann B, Zanker K, Brocker E . Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol Biol Cell. 1999; 10(10):3067-79. PMC: 25559. DOI: 10.1091/mbc.10.10.3067. View

14.

Zibert A, Balzer S, Souquet M, Quang T, Paris-Scholz C, Roskrow M . CCL3/MIP-1alpha is a potent immunostimulator when coexpressed with interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine. Hum Gene Ther. 2004; 15(1):21-34. DOI: 10.1089/10430340460732436. View

15.

Whiting D, Hsieh G, Yun J, Banerji A, Yao W, Fishbein M . Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol. 2004; 172(12):7417-24. DOI: 10.4049/jimmunol.172.12.7417. View

16.

Sharma S, Stolina M, Luo J, Strieter R, Burdick M, Zhu L . Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol. 2000; 164(9):4558-63. DOI: 10.4049/jimmunol.164.9.4558. View

17.

Qin S, Rottman J, Myers P, Kassam N, Weinblatt M, Loetscher M . The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998; 101(4):746-54. PMC: 508621. DOI: 10.1172/JCI1422. View

18.

Belperio J, Keane M, Burdick M, Lynch 3rd J, Xue Y, Li K . Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol. 2002; 169(2):1037-49. DOI: 10.4049/jimmunol.169.2.1037. View

19.

Mitchell M, Darrah D, Yeung D, Halpern S, Wallace A, Voland J . Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002; 20(4):1075-86. DOI: 10.1200/JCO.2002.20.4.1075. View

20.

Mullins I, Slingluff C, Lee J, Garbee C, Shu J, Anderson S . CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. 2004; 64(21):7697-701. DOI: 10.1158/0008-5472.CAN-04-2059. View